ArticleCancer cell international2026
Research on EBV-miR-BART17-5p targeted Inhibition of ARID1A expression to regulate nasopharyngeal carcinoma dedifferentiation.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epstein-Barr virus-encoded microRNA-BART17-5p suppresses cell proliferation and metastasis by targeting CERK.PLoS pathogens · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the role of EBV-miR-BART17-5p in promoting nasopharyngeal carcinoma (NPC) cell dedifferentiation, and to define the potential mediating function of ARID1A in this oncogenic pathway.
methodsBased on clinical NPC specimens, we analyzed EBV-miR-BART17-5p expression via qRT-PCR and its clinicopathological correlation. In vitro, lentiviral transduction was used to establish stable overexpression models in CNE1/CNE2 cells. Functional assays (CCK-8, colony formation, Transwell, tumor-sphere formation) and molecular analyses (Western blot, qRT-PCR) were performed. The targeting relationship was validated using dual-luciferase reporter assays. Immunohistochemistry assessed ARID1A and differentiation markers expression in tissue microarrays.
resultsEBV-miR-BART17-5p expression was elevated in advanced-stage and undifferentiated NPC tissues and correlated with poor patient prognosis. Functionally, it promoted NPC cell proliferation, migration, invasion, tumor-sphere formation, and induced dedifferentiation and stem-like phenotypes. Mechanistically, EBV-miR-BART17-5p directly targeted and downregulated ARID1A, whose low expression was similarly associated with advanced disease, poor survival, and a dedifferentiated phenotype. Crucially, ARID1A overexpression partially rescued the dedifferentiation effects induced by EBV-miR-BART17-5p.
conclusionThis study reveals that EBV-miR-BART17-5p promotes NPC dedifferentiation and malignant progression by targeting ARID1A, identifying a novel viral miRNA tumor-suppressor axis with therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.